Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 7, 2010, Pages 2823-2829

  Grinwis, Margot E ^a   Sibley, Christopher D ^a   Parkins, Michael D ^a,b   Eshaghurshan, Christina S ^a   Rabin, Harvey R ^a,b   Surette, Michael G ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFEPIME; CEFTRIAXONE; CLINDAMYCIN; ERYTHROMYCIN; MACROLIDE; TETRACYCLINE; ANTIINFECTIVE AGENT;

AGAR MEDIUM; AIRWAY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CLINICAL ARTICLE; CONTROLLED STUDY; DISK DIFFUSION; DRUG EXPOSURE; HUMAN; LUNG FIBROSIS; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS MILLERI; CYSTIC FIBROSIS; DRUG EFFECTS; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CLINDAMYCIN; CYSTIC FIBROSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ERYTHROMYCIN; HUMANS; MACROLIDES; STREPTOCOCCUS MILLERI GROUP; TETRACYCLINE;

EID: 77953738178     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01845-09     Document Type: Article

References (49)

1. Ahmed, R. A., T. J. Marrie, and J. Q. Huang. 2006. Thoracic empyema in patients with community-acquired pneumonia. Am. J. Med. 119:877-883.
2. Alcaide, F., J. Liñares, R. Pallares, J. Carratala, M. A. Benitez, F. Gudiol, and R. Martin. 1995. In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob. Agents Chemother. 39:2243-2247.
3. Aracil, B., J. L. Gómez-Garcés, and J. I. Alós. 1999. A study of susceptibility of 100 clinical isolates belonging to the Streptococcus milleri group to 16 cephalosporins. J. Antimicrob. Chemother. 43:399-402.
4. Asmah, N., B. Eberspacher, T. Regnath, and M. Arvand. 2009. Prevalence of erythromycin and clindamycin resistance among clinical isolates of the Streptococcus anginosus group in Germany. J. Med. Microbiol. 58:222-227.
5. Ball, J. L., R. M. Malhotra, P. Leong, and A. S. Bacon. 2000. The importance of recognising Streptococcus milleri as a cause of orbital cellulitis. Eye (Lond.) 14(5):814-815.
6. Bantar, C., L. F. Canigia, S. Relloso, A. Lanza, H. Bianchini, and J. Smayevsky. 1996. Species belonging to the Streptococcus milleri group: antimicrobial susceptibility and comparative prevalence in significant clinical specimens. J. Clin. Microbiol. 34:2020-2022.
7. Belko, J., D. A. Goldmann, A. Macone, and A. K. M. Zaidi. 2002. Clinically significant infections with organisms of the Streptococcus milleri group. Pediatr. Infect. Dis. J. 21:715-723.
8. Bourgault, A. M., W. R. Wilson, and J. A. Washington. 1979. Antimicrobial susceptibilities of species of viridans streptococci. J. Infect. Dis. 140:316-321.
9. Cade, A., M. Denton, K. G. Brownlee, N. Todd, and S. P. Conway. 1999. Acute bronchopulmonary infection due to Streptococcus milleri in a child with cystic fibrosis. Arch. Dis. Child. 80:278-279.
10. Carpenter, J., S. Stapleton, and R. Holliman. 2007. Retrospective analysis of 49 cases of brain abscess and review of the literature. Eur. J. Clin. Microbiol. Infect. Dis. 26:1-11.
11. CLSI. 2009. Performance standards for antimicrobial disk susceptibility tests. Approved standard, 10th ed. CLSI document M02-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Corredoira, J., E. Casariego, C. Moreno, L. Villanueva, M. J. Lopez Alvarez, J. Varela, A. Rodriguez, P. Alonso, and A. Coira. 1998. Prospective study of Streptococcus milleri hepatic abscess. Eur. J. Clin. Microbiol. Infect. Dis. 17:556-560.
13. de Louvois, J., P. Gortavai, and R. Hurley. 1977. Bacteriology of abscesses of the central nervous system: a multicentre prospective study. Br. Med. J. 2:981-984.
14. Doern, G. V., M. J. Ferraro, A. B. Brueggemann, and K. L. Ruoff. 1996. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob. Agents Chemother. 40:891-894.
15. Equi, A., I. M. Balfour-Lynn, A. Bush, and M. Rosenthal. 2002. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360:978-984.
16. Flume, P. A., B. P. O'sullivan, K. A. Robinson, C. H. Goss, P. J. Mogayzel, D. B. Willey-Courand, J. Bujan, J. Finder, M. Lester, L. Quittell, R. Rosenblatt, R. L. Vender, L. Hazle, K. Sabadosa, and B. Marshall. 2007. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am. J. Respir. Crit. Care Med. 176:957-969.
17. Gómez-Garcés, J. L., J. I. Alós, and R. Cogollos. 1994. Bacteriologic characteristics and antimicrobial susceptibility of 70 clinically significant isolates of Streptococcus milleri group. Diagn. Microbiol. Infect. Dis. 19:69-73.
18. Grinwis, M. E., C. D. Sibley, M. D. Parkins, C. S. Eshaghurshan, H. R. Rabin, and M. G. Surette. 2010. Characterization of Streptococcus milleri group isolates from expectorated sputum of adult cystic fibrosis patients. J. Clin. Microbiol. 48:395-401.
19. Hansen, C. R., T. Pressler, N. Hoiby, and H. K. Johansen. 2009. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients. J. Cyst. Fibros. 8:58-62.
20. Harris, J. K., M. A. De Groote, S. D. Sagel, E. T. Zemanick, R. Kapsner, C. Penvari, H. Kaess, R. R. Deterding, F. J. Accurso, and N. R. Pace. 2007. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc. Natl. Acad. Sci. U. S. A. 104:20529-20533.
21. Ishida, T., T. Hashimoto, M. Arita, I. Ito, and M. Osawa. 1998. Etiology of community acquired pneumonia in hospitalized patients. Chest 114:1588-1593.
22. Jacobs, J. A., G. J. V. Baar, N. H. London, J. H. Tjhie, L. M. Schouls, and E. E. Stobberingh. 2001. Prevalence of macrolide resistance genes in clinical isolates of the Streptococcus anginosus ("S. milleri") group. Antimicrob. Agents Chemother. 45:2375-2377.
23. Jensen, T., S. S. Pedersen, S. Garne, C. Heilmann, N. Høiby, and C. Koch. 1987. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J. Antimicrob. Chemother. 19:831-838.
24. Kobashi, Y., K. Mouri, S. Yagi, Y. Obase, and M. Oka. 2008. Clinical analysis of cases of empyema due to Streptococcus milleri group. Jpn. J. Infect. Dis. 61:484-486.
25. Laupland, K. B., T. Ross, D. L. Church, and D. B. Gregson. 2006. Population-based surveillance of invasive pyogenic streptococcal infection in a large Canadian region. Clin. Microbiol. Infect. 12:224-230.
26. Leclercq, R., and P. Courvalin. 1991. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob. Agents Chemother. 35:1267-1272.
27. Limia, A., M. L. Jiménez, T. Alarcón, and M. López-Brea. 1999. Five-year analysis of antimicrobial susceptibility of the Streptococcus milleri group. Eur. J. Clin. Microbiol. Infect. Dis. 18:440-444.
28. Moore-Gillon, J. C., S. J. Eykyn, and I. Phillips. 1981. Microbiology of pyogenic liver abscess. Br. Med. J. (Clin. Res. Ed.) 283:819-821.
29. Parkins, M. D., C. D. Sibley, M. G. Surette, and H. R. Rabin. 2008. The Streptococcus milleri group-an unrecognized cause of disease in cystic fibrosis: a case series and literature review. Pediatr. Pulmonol. 43:490-497.
30. Phaff, S. J. 2006. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. J. Antimicrob. Chemother. 57:741-746.
31. Porta, G., M. Rodriguez-Carballeira, L. Gomez, M. Salavert, N. Freixas, M. Xercavins, and J. Garau. 1998. Thoracic infection caused by Streptococcus milleri. Eur. Respir. J. 12:357-362.
32. Ramsey, B. W., H. L. Dorkin, J. D. Eisenberg, R. L. Gibson, I. R. Harwood, R. M. Kravitz, D. V. Schidlow, R. W. Wilmott, S. J. Astley, M. A. McBurnie, K. Wentz, and A. L. Smith. 1993. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 328:1740-1746.
33. Ruoff, K. L. 1988. Streptococcus anginosus ("Streptococcus milleri"): the unrecognized pathogen. Clin. Microbiol. Rev. 1:102-108.
34. Saiman, L. 2003. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290:1749-1756.
35. Shinzato, T., and A. Saito. 1995. The Streptococcus milleri group as a cause of pulmonary infections. Clin. Infect. Dis. 21(Suppl. 3):S238-S243.
36. Sibley, C. D., M. E. Grinwis, T. R. Field, M. D. Parkins, J. C. Norgaard, D. B. Gregson, H. R. Rabin, and M. G. Surette. 21 January 2010, posting date. McKay agar enables routine quantification of the Streptococcus milleri group in cystic fibrosis patients. J. Med. Microbiol. doi:10.1099/jmm.0.016592-0.
37. Sibley, C. D., M. D. Parkins, K. Duan, J. C. Norgaard, H. R. Rabin, and M. G. Surette. 2008. A polymicrobial perspective of pulmonary exacerbations exposes an enigmatic pathogen in cystic fibrosis patients. Proc. Natl. Acad. Sci. U. S. A. 105:15070-15075.
38. Sibley, C. D., M. D. Parkins, H. R. Rabin, and M. G. Surette. 2009. The relevance of the polymicrobial nature of airway infection in the acute and chronic management of patients with cystic fibrosis. Curr. Opin. Investig. Drugs 10:787-794.
39. Smyth, A. 2000. Systematic review of antistaphylococcal antibiotic therapy in cystic fibrosis. Thorax 55:251-252. (Pubitemid 30245980)
40. Stelzmueller, I., M. Biebl, N. Berger, M. Eller, J. Mendez, M. Fille, K. Angerer, T. Schmid, I. Lorenz, R. Margreiter, and H. Bonatti. 2007. Relevance of group Milleri streptococci in thoracic surgery: a clinical update. Am. Surg. 73:492-497.
41. Stutman, H. 2002. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J. Pediatr. 140:299-305.
42. Tazumi, A., Y. Maeda, C. E. Goldsmith, W. A. Coulter, C. Mason, B. C. Millar, M. Mccalmont, J. Rendall, J. S. Elborn, M. Matsuda, and J. E. Moore. 2009. Molecular characterization of macrolide resistance determinants [erm(B) and mef(A)] in Streptococcus pneumoniae and viridans group streptococci (VGS) isolated from adult patients with cystic fibrosis (CF). J. Antimicrob. Chemother. 64:1-6.
43. Tracy, M., A. Wanahita, Y. Shuhatovich, E. A. Goldsmith, J. E. Clarridge, and D. M. Musher. 2001. Antibiotic susceptibilities of genetically characterized Streptococcus milleri group strains. Antimicrob. Agents Chemother. 45:1511-1514.
44. Tramper-Stranders, G. A., T. F. W. Wolfs, A. Fleer, J. L. L. Kimpen, and C. K. van der Ent. 2007. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis. Pediatr. Infect. Dis. J. 26:8-12.
45. Tumgor, G., U. Celik, D. Alabaz, S. Cetiner, A. Yaman, D. Yildizdas, and E. Alhan. 2006. Aetiological agents, interleukin-6, interleukin-8 and CRP concentrations in children with community- and hospital-acquired pneumonia. Ann. Trop. Pediatr. 26:285-291.
46. Weisblum, B. 1995. Erythromycin resistance by ribosome modification. Antimicrob. Agents Chemother. 39:577-585.
47. Wolter, J., S. Seeney, S. Bell, S. Bowler, P. Masel, and J. Mccormack. 2002. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 57:212-216.
48. Wong, C. A., F. Donald, and J. T. Macfarlane. 1995. Streptococcus milleri pulmonary disease: a review and clinical description of 25 patients. Thorax 50:1093-1096.
49. Yamamoto, N., T. Kubota, M. Tohyama, S. Kanamori, T. Shinzato, F. Higa, M. Tateyama, and A. Saito. 2002. Trends in antimicrobial susceptibility of the Streptococcus milleri group. J. Infect. Chemother. 8:134-137.